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Abstract     211 words 34 
Current vaccination against Streptococcus pneumoniae uses vaccines based on capsular 35 
polysaccharides from selected serotypes, and has led to non-vaccine serotype replacement 36 
disease. We have investigated an alternative serotype-independent approach, using 37 
multiple-antigen vaccines (MAV) prepared from S. pneumoniae TIGR4 lysates enriched for 38 
surface proteins by a chromatography step after culture under conditions that induce 39 
expression of heat shock proteins (Hsp, thought to be immune adjuvants). Proteomics and 40 
immunoblots demonstrated that compared to standard bacterial lysates, MAV was enriched 41 
with Hsps and contained several recognised protective protein antigens, including 42 
pneumococcal surface protein A (PspA) and pneumolysin (Ply). Vaccination of rodents with 43 
MAV induced robust antibody responses to multiple serotypes, including non-pneumococcal 44 
conjugate vaccine serotypes. Homologous and heterologous strains of S. pneumoniae were 45 
opsonised after incubation in sera from vaccinated rodents. In mouse models, active 46 
vaccination with MAV significantly protected against pneumonia, whilst passive transfer of 47 
rabbit serum from MAV vaccinated rabbits significantly protected against sepsis caused by 48 
both homologous and heterologous S. pneumoniae strains. Direct comparison of MAV 49 
preparations made with or without the heat-shock step showed no clear differences in 50 
protein antigen content and antigenicity, suggesting that the chromatography step rather 51 
than Hsp induction improved MAV antigenicity. Overall, these data suggest that the MAV 52 
approach may provide serotype-independent protection against S. pneumoniae. 53 
 54 
Keywords: Streptococcus pneumoniae, vaccine, protein antigens, multiple-antigen vaccine   55 
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Introduction 56 
Streptococcus pneumoniae is a common cause of community-acquired pneumonia (CAP), 57 
septicaemia and meningitis (1), as well as of non-invasive diseases such as acute otitis 58 
media (AOM) and bronchitis (2). Over 90 different serotypes of S. pneumoniae have been 59 
identified, determined by the characteristics of the capsular polysaccharide (CPS) (3). There 60 
are currently two vaccines available to prevent S. pneumoniae infections – the 61 
pneumococcal polysaccharide vaccine (PPV) and the pneumococcal conjugate vaccine 62 
(PCV).  Each consists of capsular polysaccharide antigen from a limited panel of S. 63 
pneumoniae serotypes. In the UK, PPV remains the first choice for adult vaccination (4) and 64 
PCV is routinely included in childhood immunisation schedules worldwide as it has greater 65 
efficacy in infants than the PPV. Unfortunately, in developing countries the high cost of PCV 66 
restricts its availability, and in addition serotype coverage is reduced as PCV was designed 67 
to include the most prevalent serotypes in North America (5). Furthermore, serotype 68 
replacement in response to PCV vaccination alters the ecology of S. pneumoniae, reducing 69 
the efficacy of polysaccharide vaccines over time (6). A vaccine based on protein antigens 70 
may provide a low cost alternative approach capable of inducing cross-serotype protection 71 
(7, 8). 72 
 73 
One vaccine approach dependent on protein antigens is a whole cell approach, a cost-74 
effective method of immunising with a large number of potential protein antigens to 75 
potentially induce serotype-independent protective immunity. In addition, a whole cell 76 
approach could target both humoral and cellular host immunity (9, 10), potentially enabling 77 
clearance of both disease and colonisation. Several groups have therefore studied a whole 78 
cell vaccine approach against S. pneumoniae, including progression to early phase clinical 79 
trials (11–13).  An alternative to maintaining protein antigens as part of whole S. pneumoniae 80 
bacterium is using a bacterial lysate as a vaccine, which could result in a more stable 81 
preparation that is better suited to vaccine delivery than a whole bacterium.  However, the 82 
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antigenicity of whole cell lysates maybe weak and require enhancing (14). One method of 83 
enhancing immunogenicity is altering the preparation of the lysate to ensure increased 84 
representation of immunoprotective proteins. This can be partially achieved using anion 85 
exchange chromatography with a pH 8.0 buffer to preferentially capture several well known 86 
S. pneumoniae antigens which all have a pI of 7.5 or lower, including PiuA, PiaA, PsaA, 87 
RrgA, RrgB, ClpP, PspA and Ply. In addition, growth under stress conditions such as high 88 
temperatures to induce heat shock proteins (Hsps) could increase antigenicity (15) as Hsps 89 
facilitate the cross-presentation of peptides (16, 17) and act as natural adjuvants by 90 
stimulating macrophages and dendritic cells to cause cytokine secretion (18–20). As a result, 91 
Hsps have been studied as vaccines that protect against cancer as well as microbial 92 
pathogens (21), with a number of bacterial Hsps showing promise as vaccine candidates 93 
(22–24), including in a models of lethal lung infection (25–27). For example, mice 94 
intranasally immunised with the S. pneumoniae Hsp DnaJ (Hsp40) or Hsp caseinolytic 95 
protease P (ClpP) were protected from S. pneumoniae infection, including against systemic 96 
challenge with a panel of heterologous strains (28). Hence Hsps are potential vaccine 97 
antigens with advantageous immunomodulatory properties that could be used as a 98 
component of a broadly protective S. pneumoniae vaccine. 99 
 100 
Here we present data on a multiple-antigen approach to a novel S. pneumoniae vaccine 101 
based on bacterial lysates that combines the advantages of a whole cell approach with the 102 
potential additional benefit of increased Hsps and surface antigens content in the vaccine 103 
preparation.   104 
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Materials and Methods 105 
Bacterial strains and growth conditions 106 
S. pneumoniae was grown in either Todd-Hewitt medium (THY; Oxoid, UK) containing 5% 107 
yeast extract or the defined Hoeprichs’ media, and on 5% blood Columbia agar (Oxoid) 108 
plates containing 5% defibrinated horse blood (TCS Biosciences, UK) at 37 C 5% CO2. 109 
Growth in medium was assessed using optical density (OD) at 580-600 nm, with bacterial 110 
stocks grown to mid-log phase (OD580nm 0.4-0.5) before storage in 10% glycerol at -80 C. 111 
Bacterial counts were determined as previously described (29–31) by plating 10-fold serial 112 
dilutions of aliquots on 5% blood Columbia agar plates after overnight incubation at 37 °C in 113 
5% CO2. The TIGR4 strain-derived multiple-antigen vaccine (MAV) was made from S. 114 
pneumoniae TIGR4 (American Type Culture Collection ATCC® BA-334™), and MAV 115 
batches IPS004, IPS005 and IPS014 from TIGR4 B7.1 (PlyD6) which expresses an 116 
inactivated pneumolysin toxin made as previously described (32). Additional S. pneumoniae 117 
strains used in this manuscript were: D39 (serotype 2); 0100093 (serotype 3); 23F, a gift 118 
from Prof B Spratt (Imperial College London); 18C, from the ATCC (ATCC® BAA-1662™), 119 
EF3030 (serotype 19F), a gift from Prof D Briles (University of Alabama); Strain 1777/39 120 
(19A), a gift from Prof J Paton (University of Adelaide). 121 
 122 
MAV, Heat-killed lysate and heat-killed whole cell preparation 123 
MAV were made from S. pneumoniae TIGR4 cultured in Hoeprichs’ media (made in-house) 124 
in 1 L shake flasks at 37°C to an of OD600 of 1.2 before heat shocked at 42°C for 30 minutes. 125 
This step was omitted for the non-heat shocked preparation MAVIPS005. Bacteria were then 126 
centrifuged twice with wash buffer (40 mM Tris, 150 mM NaCl, 1 mM MgCl2, pH 8.0), 127 
incubated with lysis buffer (40 mM Tris, 20 mM NaCl, 1 mM MgCl2, and 0.5% w/v sodium 128 
deoxycholate (NaDOC), pH 8.0) for 1 h at 4°C, before homogenisation (EmulsiFlex C5 high 129 
pressure homogeniser, Avestin, Germany), and incubation with 0.1% w/v octaethylene glycol 130 
monododecyl ether (C12E8) for 4 h at 4 °C. Sample supernatants were harvested using a 5 131 
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mL Capto Q column (GE Healthcare, UK). Protein was eluted and collected as 5 mL 132 
fractions at 400 mM and 500 mM concentrations of NaCl. IPS004 and IPS014 MAV batches 133 
were made as described above using the TIGR4 B7.1 (PlyD6) with heat shock at 37°C for 30 134 
minutes, and lysis of IPS004 in NaDOC (0.5%) and C12E8 (0.1%) and of IPS014 in NaDOC 135 
(0.5%) and Triton-X 100 (1%). For heat-killed TIGR4 lysates (HKL) and heat-killed whole cell 136 
(HKWC) preparations TIGR4 were also cultured in Hoeprichs’ media in 1 L shake flasks at 137 
37°C to an of OD600 of 1.2,  followed by killing by incubation at 65 °C for 45 minutes which 138 
was confirmed by culture on Columbia agar plates. For the HKL, lysis using NaDOC and 139 
high pressure homogenisation was as described above. C12E8 was added to both the HKL 140 
and HKWC before filtration. 141 
 142 
Vaccine characterisation 143 
Vaccine samples were analysed with SDS-PAGE using a 4-12% NuPage gel (Invitrogen, 144 
USA), MES (Invitrogen) running buffer, and staining for protein with InstantBlue (Expedeon, 145 
UK). For Western blot analysis, gels were subsequently blotted onto polyvinylidene fluoride 146 
(PVDF) membranes and probed with the appropriate antibodies diluted in 5% milk / PBS: 147 
anti-Hsp60 (GroEL; SPS-875; StressGen, USA) at 1:2000; anti-pneumolysin (ab49568; 148 
Abcam, UK) at 1:2000; anti-Hsp70 (made in-house) at 1:500; anti-PspA (sc17483, Santa 149 
Cruz, USA) at 1:1000. Protein concentrations were determined using bicinchoninic 150 
acid protein assays (Pierce, USA). For haemolysis assays vaccine preparations were serial 151 
diluted in phosphate-buffered saline (PBS) and an equal volume of 2% defibrinated horse 152 
blood added and incubated at 37°C for 30 minutes followed by centrifugation at 1000 g for 1 153 
minute, and measuring the absorbance of the supernatants at 490 nm. 154 
 155 
Capillary gel electrophoresis 156 
Analysis of samples by capillary gel electrophoresis (CGE) was conducted by deltaDOT, 157 
London BioScience Innovation Centre, using the high performance capillary electrophoresis 158 
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(HPCE) platform, PEREGRINE. Peaks were manually selected and raw data was expressed 159 
as peak area corrected for migration time and then expressed as a percentage of the total 160 
corrected peak area or AUC (inclusive of triton peak (peak 1) and inter-peak regions (A – 161 
G)), normalised to an external protein standard. This compensates for day-to-day variation 162 
and allows comparison between runs on different ‘sections’ of capillary. Peak 1 is the 163 
detergent triton peak. 164 
 165 
In vitro assays 166 
S. pneumoniae whole cell ELISAs were performed using bacterial cultures at an OD580 of 167 
0.4-5, alkaline phosphatase (AP) conjugated secondary antibodies, and the substrate para-168 
nitrophenylphosphate (pNPP) (Sigma) as previously described (33, 34). Absorbance was 169 
read at 450 nm, subtracting readings at 630 nm (Versamax). The ELISA titre represents the 170 
theoretical sample dilution that would result in an OD450-630 of 0.1. For detection of anti-Ply 171 
and anti-PspA antibodies, the appropriate antigen was was diluted in carbonate buffer to a 172 
final concentration of 1 µg/mL and 100 µL was transferred to each well of a 96 well Maxisorp 173 
ELISA plate, and incubated overnight at 4 °C. Plates were then washed x 3 with ELISA wash 174 
buffer (1% v/v Tween-20 / PBS), blocked for 1 h with block buffer (1 % w/v BSA / PBS) at 37 175 
°C then washed as previous. Serum samples were diluted to a starting dilution of 1/100 to 176 
1/300. Doubling dilutions of the pooled sera samples were assayed in duplicate. Plates were 177 
incubated at 37 °C for 1 h, washed and goat anti-mouse IgG HRP diluted to 1/20,000 in 178 
added  before incubation at 37 °C for 1 h, before washing. TMB substrate was added before 179 
incubation at room temperature in the dark. Plates were read OD450 nm and end point titres 180 
were calculated using the linear part of each titration curve. IgG surface-binding was 181 
assessed using previously described flow cytometry assays (35–37) and species appropriate 182 
secondary antibodies: anti-human IgG secondary antibody (1:200) conjugated to PE (Sigma-183 
Aldrich); goat anti-mouse IgG, conjugated to FITC (Bio-Rad, USA). FACS analysis of 184 
bacterial cells was performed on the FACSVerse flow cytometer (Becton Dickinson, USA), 185 
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and FACSuite (Becton Dickinson) and FlowJo (Becton Dickinson) software. FACs surface 186 
binding comparisons of MAVIPS004 and MAVIPS005 were conducted by ImmBio: 100 µL of 187 
bacterial suspension was placed in each 5 mL FACS tube and incubated overnight at 4ºC. 188 
Cells were washed with PBS/0.1% Tween 20 (PBS-T). Pre-adsorbed sera samples were 189 
diluted serially (two-fold) starting from 1 in 25 to 1 in 800 in PBS / 1% BSA. Cells and sera 190 
were incubated together for 2 hours at room temperature and then washed with PBS-T. Goat 191 
anti-mouse IgG detection antibody in PBS / 1% BSA was added and incubated for 2 hours. 192 
Cells were then fixed with formalin for 30 minutes at room temperature. Following washing in 193 
PBS-T, samples were resuspended in PBS / 1% FCS. The mean fluorescence intensity 194 
(MFI) was read by flow cytometry requiring 100,000 events for each sample. The mean 195 
fluorescence intensity (MFI) multiplied by the number of cells in quadrant 1 is shown for each 196 
serotype. This represents the degree of antibody binding to each serotype.  Multiplexed-197 
electroluminescence assays were conducted as previously described (38–40) using a Meso 198 
Scale Discovery (MSD, MD USA) platform assay (41) and 5 μg/ml of S. pneumoniae 199 
proteins and 10 μg/ml of capsular polysaccharide. After incubation of each antigen-coated 200 
plate with blocking agent, washing, and incubation with diluted test sera for 45 min at room 201 
temperature, plates were washed and MSD Sulfo-Tag-labelled goat anti-mouse IgG 202 
secondary antibody added for reading using a MSD SECTOR Imager 2400 or 6000. 203 
 204 
Quantitative comparison of protein content using Tandem Mass Tags (TMT) 205 
and mass spectrometry (MS) 206 
TMT labelling procedure followed manufacturer’s recommendation (Thermo Fisher). In brief 207 
protein lysates from two replicates of HKL and MAV were reduced with tris(2-carboxyethyl) 208 
phosphine and alkylated with iodoacetic acid before an overnight acetone precipitation. 209 
Protein pellets were digested overnight at 37oC in 200 mM TEAB solution containing 2.5 µg 210 
trypsin (Promega) with the resulting peptides labelled with different isobaric tags (Tandem 211 
Mass Tags, TMTs 126 – 128). Labelled peptides were mixed and injected on to an XBridge 212 
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C18 co lumn, (5 µm, 4.6 mm id and 25 cm long; Waters) for the first dimension high pH RP-213 
HPLC separation under a linear gradient consisting of mobile phase A (10 mM ammonium 214 
formate, pH 10.0) and up to 70% B (90% acetonitrile in mobile phase A) for 2 hours at flow 215 
rate of 0.5 mL/min, using a Jasco system consisting an autosampler, semi-micro HPLC 216 
pumps and UV detector. Eluted fractions were collected and concatenated into eighteen 217 
tubes and vacuum dried. 218 
 219 
Nano-LC and MS/MS was performed using a U3000 direct nano system coupled with nano-220 
electrospray and LTQ-Orbitrap Discovery mass spectrometer (Thermo). The twelve HPLC 221 
fractions containing the mixture of fourplex labelled peptides were resuspended in 0.1% 222 
formic acid and each was separated on a PepMap C18 reversed phase nano column (3 m, 223 
100Ǻ, 50 cm length; Thermo) under a column flow rate of 0.3 µl/min using linear gradient of 224 
5 – 25% for 180 min, 25 – 32% for 20 min and 32 – 90% for 10 min of 95% acetonitrile and 225 
0.1% formic acid. MS scan and MS/MS fragmentation were carried out in Orbitrap and LTQ 226 
respectively using 2 cycles of top 3 data-dependent acquisition with dynamic exclusion mode 227 
enabled and total cycle time at approximately 30 milliseconds. The first cycle used collision-228 
induced dissociation (CID) fragmentation generating spectra for peptide sequencing, and the 229 
second High energy CID (HCD) generating spectra both for peptide sequencing and relative 230 
quantitation via report ions. 231 
 232 
Mass spectra processing, database searching and quantitation were performed using 233 
Thermo Proteome Discoverer 1.4 with built-in Sequest against UniProt S. pneumoniae 234 
FASTA database, (release (2014.04.03). Spectra from the 12 fractions were added together 235 
as one sample during searching. Initial mass tolerances by MS were set to 10 ppm. Up to 236 
two missed tryptic cleavages were considered. Methionine oxidation was set as dynamic 237 
modification whereas carboxymethylation on cysteine and TMT6plex labels on N-terminal 238 
amino acid and lysine side chain were set as static modifications. Peptides at rank 1 with 239 
high confidence are considered to be unambiguously sequenced. Quantification was based 240 
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on the relative abundances of TMT tag as the reporter ions for each peptide in the HCD 241 
spectra with all TMT channels present. Ratios were calculated from relative abundances of 242 
each labelled peptide in the sample based on reporter ion intensities and for every protein 243 
identified, each was assigned a series of quantification ratio relative to each group. 244 
 245 
In vivo methods 246 
All in vivo experiments using mice were performed according to UK national guidelines for 247 
animal use and care. Experiments performed at UCL were approved by the UCL Biological 248 
Services Ethical Committee and the UK Home Office (Project Licence PPL70/6510). 249 
Experiments used 6 week old outbred female CD1 mice obtained from Charles River 250 
Laboratories. Mice were vaccinated with 75 µg of protein in 100 µL PBS using either 251 
intraperitoneal injection at day 0, 14 and 28 or subcutaneous (SC) vaccination on day 0 and 252 
21. Tail bleeds (5μL per mouse) were collected on day 42 and mice challenged with S. 253 
pneumoniae on day 49. For the pneumonia model mice were inoculated with 5 x 106 CFU of 254 
S. pneumoniae in PBS intranasally (IN) under isoflurane (4%; MiniRad) anaesthesia. After 255 
either 24 or 48 h, the mice were euthanized with pentobarbitone, and blood, sera, 256 
bronchoalveolar lavage fluid (BALF), lung, and spleen collected as previously described (9, 257 
36, 42, 43). Lungs and spleens were macerated through a 0.2 µm filter. For the colonisation 258 
model, mice were anaesthetised with aerosolised isoflurane (4%) and inoculated with 5 x 106 259 
CFU S. pneumoniae suspended in 10μl of PBS.  At designated time points post-infection the 260 
mice were culled and the nasal washes obtained by retrograde washing of the nares with 261 
500 µL PBS via the trachea. To assess survival, mice were vaccinated by intraperitoneal 262 
inoculation with 75 µg of the MAVIPS014 vaccine together with the adjuvant system (Sigma, 263 
S6322) on day 1, 10 and 22 before intranasal challenge with 1x107 CFU TIGR4 S. 264 
pneumoniae on day 50. Disease development was monitored over 6 days and mice culled 265 
when exhibiting signs of severe disease (42).  For the passive transfer model mice were 266 
injected intraperitoneally (IP) with 200 μl of serum harvested from rabbits vaccinated by SC 267 
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injection with 375 g MAV on days 0, 21 and 35, or with 2 x 200 L Prevenar 13 (day 0 and 268 
21) at Envigo, UK. Mice were challenged 6 hours later by IP inoculation of 1 x 104 CFU of S. 269 
pneumoniae and culled at 24 h to obtain blood samples for plating.  For the sepsis model, 270 
sera from vaccinated mice or rabbits were transferred to mice via intravenous (IV) injections 271 
to the lateral tail vein. After 4 h, the mice were inoculated IV with 5 x 105 CFU of S. 272 
pneumoniae, and culled 4 h later to collect blood. For the pre-opsonisation clearance model 273 
S. pneumoniae were opsonised by incubation in 100% of rabbit immune serum for 1 h at 37 274 
°C, then 5 x 105 CFU S. pneumoniae were inoculated IV into mice which were then culled 4 275 
h later to obtain blood for CFU quantification by plating. To calculate target organ CFU 276 
aliquots of blood, lung and spleen tissues were plated at appropriate dilutions on 5% blood 277 
Columbia agar plates containing 5mg/mL gentamicin (Sigma).  Additional experiments to 278 
raise antisera with different vaccine preppartions were performed at a commercial 279 
organisation, Churchill Applied Biotechnology Ltd, according to institutional guidelines under 280 
their UK Home Office Project Licence. For these experiments, six groups of female CD-1 281 
mice (n=10) were immunised subcutaneously with the 0.75g of MAV on day 0 and day 21. 282 
Mice were culled on day 35 and terminally bled, and sera prepared for the investigation of 283 
antibody responses. 284 
 285 
Flow cytometry phenyotypic screening of inflammatory cell populations   286 
Lungs of vaccinated mice were harvested 24 hours after infection and single cell 287 
suspensions prepared by homogenating the tissues and filtering them with 100µm cell 288 
strainers. Red blood cells were lysed with RBC lysis buffer (Biolegend, 420301) and washed 289 
cells were resuspended at a concentration of 106 cells/ml in blocking buffer (PBS-1% BSA 290 
containing anti-Fc receptor antibodies (Biolegend, TruStain FcX™)). The cells were seeded 291 
in round-bottom 96-well plates (100 μl/well) and incubated for 30 min on ice. Cells were 292 
washed and stained with a mixture of antibodies diluted 1:100 for 30 minutes in ice. The 293 
antibodies used were: anti-mouse CD19 Brilliant Violet 480 (BD Bioscience, 566167), anti-294 
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mouse CD11c PE-Cy7 (Biolegend, 117317), anti-mouse Ly-6G PerCP-Cy5.5 (Biolegend, 295 
127615), anti-mouse F4/80 Brilliant Violet 421 (Biolegend, 123131), anti-mouse CD3 PE 296 
(Biolegend, 100205), anti-mouse CD4 APC  and anti-mouse CD8 APC-Cy7 (Biolegend, 297 
100713). The cells were washed three times with PBS and stained with Zombie Green 298 
Fixable viability kit (Biolegend, 423111) (1:500) for 15 min according to the manufacturer’s 299 
instructions. After two extra washes with PBS-1% BSA cells were fixed with 300 
paraformaldehyde (PFA) and fluorescence assessed using a XX (BD Bioscience, UK).  The 301 
samples were analysed on a FACS Verse flow cytometer (BD Bioscience). 302 
Neutrophil/monocyte population and the lymphocyte populations were initially identified 303 
using forward and side scatter dimensions and the immune sub-populations were defined as 304 
follows: macrophages CD11c+ F4/80+ Ly-6G-, neutrophils Ly-6G+ CD11c- F4/80-, B cells 305 
CD19+ CD3-, and T cells CD3+ CD19-. T cells population were further subdivided using 306 
CD4 and CD8 markers. Lung homogenate cytokines levels (IL-1, IL-6, IL-10, TNF-α ) were 307 
determined by using a Luminex magnetic bead array assay (R&D systems) according to 308 
manufacturer protocols. 309 
 310 
Statistical methods 311 
Statistical analyses were conducted using Prism 7 (Graph Pad, USA). Parametric data are 312 
presented as means, and error bars represent standard deviation. Comparisons between 313 
multiple groups were conducted using analysis of variance and the Holm-Sidak or Dunnett’s 314 
post-test to compare between experimental groups. Non-parametric date were analysed 315 
using the Mann-Whitney U test.   For the disease development model, data were analysed 316 
using the log-rank (Mantel-Cox) test.  317 
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Results  318 
Formulation of a S. pneumoniae MAV 319 
A multiple-antigen Hsp-enriched preparation based on a whole cell preparation was 320 
formulated using the ImmBio platform technology as previously described (32). Heat shock 321 
was used to enrich for Hsps and anion exchange chromatography to enrich for negatively 322 
charged S. pneumoniae antigens (e.g. PspA and Ply) (Fig. 1A). Immunoblots determined 323 
which elution fractions contained the highest concentration of Hsp60 and Hsp70 protein, and 324 
demonstrated a marked increase in the expression of both Hsp60 and 70 content in the MAV 325 
compared to bacterial heat-killed lysate (HKL) (Fig. 1B and C). A pooled human IgG 326 
preparation known to recognise multiple S. pneumoniae protein antigens (9) was used to 327 
probe MAV and HKL to determine whether there were differences in their non-Hsp protein 328 
content. This demonstrated variations in number, intensity and molecular weights of bands 329 
identified after incubation in sera from MAV or HKL vaccinated animals (Fig. 1D). Ply activity 330 
in the MAV, HKL and a heat-killed whole cell (HKWC) preparation formulated with the wild-331 
type TIGR4 strain was assessed using a haemolysis assay. HKWC and HKL did not cause 332 
lysis of red blood cells, probably due to degradation of Ply during the heat-killing step, 333 
whereas MAV caused red cell lysis, suggesting the MAV preparation still contained active 334 
Ply (Fig. 1E). 335 
 336 
Proteomic analysis of MAV preparations 337 
MS/MS sequencing was used to identify proteins in the MAV and HKL preparations, with 338 
TMT labelling to assess relative protein quantitation. A total of 627 proteins were identified 339 
and compared between MAV and HKL preparations. Of these, 57 were increased >2-fold in 340 
MAV compared to HKL (Supplementary Table 1), including several Hsps and important 341 
known surface antigens such as PavB and several lipoproteins, including PsaA, PiaA, and 342 
the Th17 antigens SP_0148 and SP_2108 (44) (Table 1). Conversely, 152 proteins were 343 
decreased by more than 2-fold by the vaccine preparation process, including multiple 344 
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proteins required for basic metabolic functions (e.g. ribosomal proteins) and capsule 345 
synthesis, but also the virulence factors and protective antigens Ply, PspA, and PspC 346 
(Supplementary Table 2). Previously we have published data obtained using deltaDOT® 347 
capillary gel electrophoresis (CGE) demonstrating consistent protein content between 348 
different batches of MAV preparations (32).  349 
 350 
Vaccination with MAV induces functional antibodies  351 
To assess immunogenicity of MAV, mice were immunised by subcutaneous injection with 352 
either MAV, HKL, HKWC or the negative control buffer using a two dose schedule 21 days 353 
apart. Whole cell ELISAs demonstrated that pooled serum obtained one week after the 354 
second vaccinaton with MAV contained markedly higher antibody responses to the S. 355 
pneumoniae TIGR4 strain than those detected in serum from HKL-vaccinated mice. No 356 
statistically significant anti-TIGR4 response was identified in sera from mice vaccinated with 357 
HKWC (Fig. 2A). The serum antibody response to MAV was dominated by IgG with no 358 
significant IgM response compared to buffer vaccinated mice (Fig. 2B). Significantly 359 
increased levels of anti-TIGR4 IgG were also detected in the BALF of mice immunised with 360 
MAV, but not in nasal washes (Fig. 2C).  Whether serum IgG induced by the MAV, HKL and 361 
HKWC preparations can recognise and bind to the surface of live S. pneumoniae was 362 
assessed using a flow cytometry assay that correlates with protection (36). Compatible with 363 
the ELISA data, when S. pneumoniae TIGR4 were incubated in serum from mice vaccinated 364 
with MAV there were higher levels of IgG binding than after incubation in serum from mice 365 
vaccinated with HKL or HKWC. Incubation in sera from HKWC vaccinated mice also resulted 366 
in less IgG binding to S. pneumoniae in comparison to sera from HKL-vaccinated mice (Fig. 367 
3A, B, C). To investigate IgG binding to heterologous strains, the IgG binding assays were 368 
repeated using S. pneumoniae serotypes 18C, 23F, 3, and 19F (EF3030) strains. Sera from 369 
MAV vaccinated mice significantly increased serum IgG binding to the 18C, 23F, 3 and 370 
EF3030 (19F) strains compared to in a buffer-vaccinated control serum (Fig. 3D, E). 371 
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 372 
Sera from MAV vaccinated mice bind to multiple protein antigens 373 
Immunoblots against S. pneumoniae lysates from TIGR4, D39 and 19A strains 374 
demonstrated that antibodies from MAV and HKL vaccinated serum recognised a number of 375 
proteins which were largely conserved between the three strains. The antigens recognised 376 
after probing with sera from MAV and HKL vaccinated mice overlapped, although a band at 377 
approximately 75kDa (potentially consisting of multiple proteins) was recognised by serum 378 
from MAV vaccinated mice but not recognised by serum from HKL vaccinated mice (Fig. 379 
4A). An MSD multiplex assay that measures IgG levels to a panel of known S. pneumoniae 380 
surface and immunogenic proteins was used to identify some of the protein antigens 381 
recognised by sera from vaccinated mice (38).  IgG in serum from MAV-vaccinated mouse 382 
recognised all the antigens included in the MSD panel proteins, including PspC (CbpA), 383 
PspA, PsaA, PiaA, PiuA, and the pilus proteins RrgA and RrgB, all of which have previously 384 
been shown to be protective vaccine candidates in mice (45–48) (Fig. 4B). In contrast, IgG in 385 
serum from HKL-vaccinated mice recognised fewer proteins with no responses to PspC, 386 
LytC, PcsB, PiaA, PiuA, family 1 PspA, SP_0609, SP_2027, Spr0057 (StrH) and StkP. 387 
 388 
Comparison of MAV preparations made with and without Hsp induction 389 
To assess the role of Hsp induction for the immunogenicity of the MAV preparations, MAV 390 
preparations were made with (MAVIPS004) and without (MAVIPS005) the Hsp induction step. 391 
Comparing the two MAV preparations using immunoblots showed no clear differences in 392 
expression of the Hsps Hsp70 and Hsp60, nor in the expression of the immunogenic 393 
proteins PspA and Ply (Fig. 5A). The capillary gel electrophoresis profiles of both 394 
preparations suggested only minor overall differences in their protein constituents of (Fig. 395 
5B). Both preparations were used to generate antisera using vaccination experiments in 396 
mice conducted at Churchill Applied Biotechnology Ltd. Sera recovered from mice 397 
vaccinated with MAVIPS004 and MAVIPS005 treated mice showed no major statistically 398 
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significant differences in flow cytometry assays of IgG binding to live S. pneumoniae or 399 
whole cell ELISA titres against the TIGR4 S. pneumoniae strain (Fig. 5C).  Specific protein 400 
antigen ELISAs demonstrated increased antibody titres to Ply in serum from mice vaccinated 401 
with the heat shock MAVIPS004 compared to those vaccinated with MAVIPS005 (Fig. 5D), and 402 
reduced titres to PspA (Fig. 5E). When measured using the MSD multiplex assay (38) there 403 
were no differences between the  two vaccine preparations in responses to other antigens 404 
(PiuA, PsaA, RrgA and RrgB, data not shown). These data indicate that the heat shock step 405 
in MAV preparation had limited effects on heat shock content or overall antigenicity. 406 
 407 
Protective efficacy of vaccination of mice with MAV TIGR4 preparations 408 
Mouse models were used to determine if vaccination with Hsp induced MAVs resulted in 409 
protective immunity against S. pneumoniae. 24 h after challenge using the pneumonia 410 
model, mice vaccinated with MAV had at least one log10 fewer bacterial CFU in both the 411 
blood and lungs compared to buffer-vaccinated controls (Fig. 6A and B). In contrast, MAV 412 
vaccination did not reduce the density of bacterial CFU in nasal washes obtained 2 weeks 413 
after inoculation in a model of S. pneumoniae nasopharyngeal colonisation with TIGR4 (Fig. 414 
6C).  In order to eliminate potential adverse effects caused by an active Ply, new MAV 415 
preparations termed MAVIPS004 and MAVIPS014, denoting different batches, were prepared 416 
using a mutated TIGR4 strain expressing a detoxified Ply (49). MAVIPS004 and MAVIPS014 both 417 
contained similar levels of detoxified Ply as measured by ELISA assay that stimulated an 418 
antibody response that recognised native Ply (32), and absence of haemolysis in the red 419 
blood cell assay. Rabbit sera obtained from rabbits vaccinated subcutaneously on days 0, 420 
21, 35 with 375 μg of MAVIPS004, S. pneumoniae vaccine Prevenar as a positive control, or 421 
buffer were used for passive immunisation of mice followed by intraperitoneal challenge of 1 422 
x 104 CFU TIGR4 S. pneumoniae after 6 h. When culled 24 h post-challenge, blood CFU 423 
were recovered in over 65% of the mice given sera from buffer-vaccinated rabbits whilst 424 
there were no CFU detected in mice given serum obtained from MAVIPS004 vaccinated rabbits 425 
(Fig. 6D). Two mice (16%) developed septicaemia after passive administration of sera from 426 
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rabbits given Prevenar. In an alternative sepsis model, mice were challenged by intravenous 427 
inoculation with 5 x 105 CFU of S. pneumoniae TIGR4 or ATCC® BAA-1662 (serotype 18C 428 
S. pneumoniae) strains after pre-incubation of the bacteria for 1 h in 100% rabbit sera 429 
obtained from animals immunised with MAVIPS014, Prevenar or buffer controls. Mice were 430 
culled at 4 h to assess rate of bacterial clearance from the blood by quantifying CFU. Those 431 
challenged with the TIGR4 strain were almost completely protected against infection if the 432 
bacteria were incubated in sera from either MAVIPS014 or Prevenar vaccinated rabbits pre-433 
challenge (Fig. 6E).  Pre-incubation of the 18C strain prior to intravenous challenge in sera 434 
from either MAVIPS014 or Prevenar vaccinated rabbits pre-challenge reduced bacterial CFU 435 
recovered from the blood by over one log10 compared to pre-incubation in sera from buffer 436 
vaccinated rabbits (Fig. 6F). To support these data vaccination with MAVIPS014 was compared 437 
to a buffer control in a protection study, which demonstrated that mice given a three dose 438 
vaccination schedule with MAVIPS014 were protected against the development of fatal 439 
infection after pneumonia challenge with TIGR4 (Fig. 7A). The effects of vaccination on the 440 
inflammatory response to pneumonia challenge was assessed using flow cytometry of lung 441 
and BALF cell populations 24 h after intranasal infection with TIGR4. Despite clear 442 
reductions in lung and blood CFU in vaccinated mice, there were no differences in the 443 
proportions of neutrophils in BALF between MAV- or buffer-vaccinated mice, indicating MAV-444 
vaccination resulted in an increased BALF neutrophil response for the level of bacterial 445 
infection (Fig. 7B, C).  In addition, in lung homogenates MAV vaccinated mice had reduced 446 
proportions of neutrophils and macrophage lineage cells and a corresponding increase in T 447 
cells (Fig. 7D).  The increase in T cell proportion within lung homogenates in vaccinated 448 
mice did not alter the CD4 / CD8 proprtions compared to the data for control mice (data not 449 
shown).  Lung homogenate cytokine levels were variable between mice but showed 450 
increased IL1, IL6, TNFalpha, and IL10 responses in vaccinated mice compared to controls, 451 
again suggesting vaccinated mice were able to mount a more sustained inflammatory 452 
response than controls (Fig. 7 E-H). BALF and blood cytokine levels were in general too low 453 
and variable for consistent patterns to be identified. 454 
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 455 
Overall, these results indicate that the MAV is able to protect against S. pneumoniae 456 
infection with the homologous or a heterologous strain at a similar level of protection to that 457 
provided by Prevenar, and associated with significant changes in the inflammatory response 458 
to pneumonic infection.  459 
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Discussion 460 
Although the existing childhood conjugated capsular polysaccharide S. pneumoniae 461 
vaccines are highly effective, the lack of both protection against non-vaccine serotypes and 462 
convincing evidence of serotype replacement in vaccinated populations, as well as the high 463 
cost of these vaccines, has stimulated continued interest in alternative vaccine approaches 464 
(50, 51). Vaccines based on protein antigens could overcome these disadvantages, allowing 465 
production of relative cheap vaccines that target cross-protective antigens (52–55). 466 
Presentation of a large number of protein antigens derived from a whole cell approach has 467 
the additional potential advantages of inducing immune responses to multiple antigens, 468 
thereby potentially avoiding vaccine escape mutants developing and inducing stronger 469 
cross-protective responses (56, 57). 470 
 471 
The data presented here shows that a novel S. pneumoniae multiple protein antigen vaccine 472 
approach induces antibody that recognises homologous and heterologous strains, and 473 
protects against invasive pneumonia and sepsis. The MAV approach uses a whole cell 474 
lysate that has been manipulated to increase expression of Hsps and the anion exchange 475 
column and running buffer are optimised for the capture of known S. pneumoniae antigens 476 
as well as Hsp proteins. Proteomic analysis confirmed that the MAV approach alters relative 477 
levels of S. pneumoniae proteins within the preparation compared to a simple bacterial 478 
lysate, with altered expression of a total of 209 proteins of the 627 proteins analysed. The S. 479 
pneumoniae TIGR4 strain actually contains approximately 2000 genes (58), so the number 480 
of proteins with altered content in the MAV may in fact be substantially larger. Both 481 
immunoblotting and TMT-MS confirmed that the MAV had increased Hsp content compared 482 
to a simple lysate.  In addition, there was increased expression of multiple surface proteins 483 
including known protective antigens (mainly lipoproteins), although there were also reduced 484 
amounts of other protein antigens that are known to induce protective immunity in mice. 485 
 486 
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Importantly, whole cell ELISAs, MSD for IgG responses to individual antigens, or a flow 487 
cytometry assay of IgG binding to S. pneumoniae all demonstrated enhanced antibody 488 
responses in mice vaccinated with the MAV compared to the HKL, demonstrating the benefit 489 
of the MAV approach in making a potentially more effective vaccine. Unlike HKL, MAV 490 
induced antibody responses to all the protein antigens tested using the MSD system 491 
suggesting that the MAV approach may induce antibody responses to a very high proportion 492 
of the proteins in the preparation. Furthermore, although iTRAQ demonstrated reduced 493 
content in the MAV preparation compared to HKL for the important antigens PspC and Ply, 494 
vaccination with MAV still induced stronger IgG responses to these antigens when tested 495 
using MSD than HKL. These data again suggest the MAV approach enhances 496 
immunogenicity. The improved serological responses to MAV compared to HKL might be 497 
predicted to be due to the increased Hsps content leading to formation of Hsp-peptide 498 
complexes and thereby increasing antigen presenting ability (27, 32).  However, direct 499 
comparison of MAV preparations with or without a heat shock step as vaccines in mice did 500 
not show any major differences in protein content (including Hsp 60 and 70) or in 501 
immunogenicity apart from a reduction in antibody responses to PspA. These data suggest 502 
that the anion exchange chromatography step alone enhances immunogenicity of the MAV 503 
preparations, and seems to increase heat shock protein content independent of the heat 504 
shock step. In addition, the lower temperature used for making MAV preparations compared 505 
to that required for making HKL preparations could have allowed some proteins to retain 506 
stronger immunogenicity. 507 
 508 
Data from a pneumonia and two separate sepsis mouse models demonstrated active or 509 
passive vaccination with MAV improved protection against S. pneumoniae. Time course 510 
experiments carried demonstrated that vaccination with the MAV preparation delayed and 511 
protected against lethal infection. The total T cell populations in the lung were also increased 512 
in MAV-vaccinated mice. This effect in T cell proportions probably reflects the accumulation 513 
of antigen specific cells during pneumonia in infected tissue, but further experiments would 514 
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be needed to confirm this. Overall the data demonstrate vaccination with MAV had 515 
significant effects on the inflammatory response during S. pneumoniae pneumonia that is 516 
likely to contribute to protective efficacy, with improved neutrophil recruitment into the 517 
alveolar space and increased numbers of T cells within the lung parenchyma.  518 
 519 
MAV also induced IgG that bound to heterologous strains in the flow cytometry assay, an 520 
assay which correlates with improved phagocytosis in vitro and in protection in mouse 521 
models (35–37). Indeed, in a mouse model of sepsis passive vaccination with sera from 522 
MAV-vaccinated rabbits gave a similar level of protection against both the homologous 523 
TIGR4 and heterologous 19C strains as passive vaccination with sera from Prevenar 524 
vaccinated rabbits.  Whether vaccination with MAV can induce stronger protection than 525 
vaccination with HKL or HKWC in the mouse models has not been tested; due to the 526 
relatively low sensitivity of the mouse models this is likely to require inappropriately large 527 
numbers of mice per test group. Lack of sensitivity is also why vaccination followed by 528 
disease challenge experiments would be unlikely to show any significant differences 529 
between MAV preparations with and without heat shock steps, and why these experiments 530 
were not performed. The level of protection varied between models, with complete 531 
prevention of septicaemia in some models e.g. IV TIGR4 infection, versus reductions in 532 
bacterial CFU in the blood only (e.g. 18C serotype sepsis model). The latter is likely to slow 533 
the progression of disease but not prevent fatal infection. Vaccination with MAV failed to 534 
protect against colonisation, but this is not that surprising given the lack of detectable 535 
antibody in nasal washes and previous data showing that anti-protein antibody is often 536 
ineffective at reducing nasopharyngeal S. pneumoniae CFU (in some cases, even when 537 
Th17 mediated immunity has also been induced) (9, 10, 61). Prevention of nasopharyngeal 538 
colonisation will probably require vaccines that induce strong cell-mediated immune 539 
mechanisms, which may require vaccination in combination with specific adjuvants (24, 43, 540 
58). This would be an important area for further investigation. Future experiments should 541 
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also assess whether MAV vaccination modulates pulmonary inflammatory responses to S. 542 
pneumoniae pneumonia challenge.  543 
 544 
The MAV approach described here can induce cross-protective immunogenicity of protein 545 
antigens which stimulate antibody and perhaps Th17 cell responses (44, 63) without 546 
requiring the identification of specific protective antigens nor production of recombinant 547 
proteins for inclusion in subunit vaccines. MAV requires limited downstream processing and 548 
rapidly produces a high yield of vaccine product, considerably reducing vaccine costs and 549 
making the vaccine more likely to be affordable in low and middle income countries. The 550 
MAV approach therefore offers a promising opportunity for a novel next generation S. 551 
pneumoniae vaccine, and has recently completed a phase I trial in 36 subjects (Clinical Trial 552 
Registry Number: NCT0257635; 59).  553 
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Figures 787 
 788 
Figure 1  Formulation of a multiple antigen S. pneumoniae TIGR4-derived vaccine 789 
preparation (MAV). A Ion exchange (IEX) chromatogram showing the purification of the 790 
MAV. Light green line indicates NaCl elution concentration, the brown line is the resulting 791 
conductivity in the system; the blue line is the UV trace showing concentration of eluted 792 
proteins (mAu); the dark green line is the pressure in the system; fractions collected are 793 
numbered in red; total volume is recorded on the x-axis (mL). B Detection of Hsp60 and 794 
Hsp70 by Western blot in selected IEC fractions; BCA assay protein concentrations for these 795 
fractions are shown in the table. C A comparison of the heat shock protein content (Hsp60 796 
and Hsp70) as measured by immunoblotting of heat-killed lysate (HKL) and MAV. Bar chart 797 
shows pixel intensity quantification (ImageQuant TL; GE Lifesciences) for Hsp60 and Hsp70 798 
bands.  D Immunoblots of 5 μg of total protein of either MAV or HKL probed with pooled 799 
human IgG at 1:20 000 (Pentaglobin; Paviour Pharmaceuticals, New Delhi). E Comparison 800 
of the haemolytic activity against horse red blood cells in serial 2 fold dilutions of MAV from 801 
neat to 1:64 (filled circles) and HKL (squares), and HKWC (crosses) preparations, with a 802 
saponin positive control (empty circles). 803 
 804 
Figure 2  MAV is immunogenic in a mouse model of subcutaneous vaccination. CD1 805 
mice were vaccinated subcutaneously with 75 μg on day 0 and day 21, and culled at 28 806 
days to obtain serum. A Whole cell IgG ELISA against S. pneumoniae TIGR4 for pooled 807 
sera harvested from tail vein bleeds (10 µL per mouse, n = 6) B Whole cell IgG and IgM 808 
ELISAs against S. pneumoniae TIGR4 for pooled sera from MAV vaccinated mice (n = 5) 809 
and C against S. pneumoniae TIGR4 for pooled BALF and nasal washes from MAV 810 
vaccinated mice. Data are presented as mean and 95% CI. P values calculated using the 811 
Mann Whitney t test with * = p < 0.05; ** = p < 0.01. 812 
 813 
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Figure 3 Binding of immune mouse sera to the surface of S. pneumoniae strains. A 814 
IgG surface binding assays of S. pneumoniae TIGR4 incubated in sera from vaccinated mice 815 
is shown by geometric mean fluorescence index (MFI). Error bars represent SD of technical 816 
replicates. Significance is calculated with the Holm-Sidak test, with * = p < 0.05. B 817 
Representative flow cytometry histograms showing IgG positive S. pneumoniae TIGR4 818 
populations. White histogram – buffer negative control serum; black histogram – serum from 819 
MAV vaccinated mice; dark grey – serum from HKL vaccinated mice; light grey – serum from 820 
HKWC  vaccinated mice. C IgG binding to TIGR4 in immune serum diluted to 25, 12.5, 6.25 821 
and 3.125%. Data points are means of technical replicates; error bars represent standard 822 
deviations. Significance values are calculated between each dilution curve using a two-way 823 
ANOVA and compared to the buffer negative control. **** = p < 0.001. D Mean fluorescent 824 
IgG surface binding to S. pneumoniae 18C, 23F, ST3 and 19F strains incubated in sera from 825 
MAV or buffer vaccinated mice. Error bars represent standard deviations for technical 826 
replicates. Significance is calculated with the Holm-Sidak test, with * = p < 0.05. E 827 
Representative histograms showing a shift in IgG positive populations against different 828 
strains of S. pneumoniae: white histogram – IgG binding in buffer vaccinated serum; shaded 829 
histogram – binding in MAV vaccinated serum. 830 
 831 
Figure 4 Identification of protein antigens recognised by sera from vaccinated mice. A 832 
Immunoblots of S. pneumoniae TIGR4, D39 or 19A strains whole cell lysates probed with 833 
serum diluted 1:1000 from mice vaccinated with either HKL or MAV.  B Identification of 834 
protein antigens recognised by sera from vaccinated mice using MSD. Values are 835 
normalised to a negative control from buffer-vaccinated mice sera. Mean values are shown 836 
with error bars representing standard deviations for sera from mice vaccinated with MAV (n 837 
= 3, black columns); HKL vaccinated serum (n = 1, grey columns).  838 
 839 
 840 
 841 
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Figure 5 842 
A comparison of heat shocked MAV vs non-heat shocked MAV. A MAV preparations were 843 
made with (MAVIPS004) and without (MAVIPS005) the Hsp induction step. Protein bands were 844 
compared using a Coomassie gel (top). 3 μg (lanes 7 & 9) and 5 ug (lanes 8 & 10) of each 845 
MAV was loaded respectively; immunoblots of the MAV preparations were also probed for 846 
the presence of the key S. pneumoniae protein antigens (PlyD6, PspA) and Hsps (Hsp70, 847 
Hsp60). B Capillary gel electrophoresis (CGE) analysis was conducted to determine the 848 
protein constituents of each preparation. Each peak is denoted by a number, and inter-peak 849 
regions marked by a letter. Quantification of peaks is shown in the barchart on top. CGE 850 
traces are shown below. C Both MAVIPS004 and MAVIPS005 were used to generate antisera 851 
using vaccination experiments in mice. Sera recovered from mice vaccinated with either 852 
preparations were analysed using flow cytometry assays of IgG binding to live S. 853 
pneumoniae (serotpyes 1, 2 (D39), 4 (TIGR4), 6B, 8, 19A, 22F and 23F) and results are 854 
represented as mean fluorescence intensity (MFI) in the appropriate gate (Q1) D ELISAs 855 
detecting anti-Ply and E anti-PspA responses were conducted in duplicate. Sera from the 856 
experiments described above were diluted as shown on the x-axis, and OD 450 nm was 857 
measured for each MAV, and a buffer control. Abbreviations: MAV, multi-antigen vaccine; 858 
HS, heat shocked; NHS, non-heat shcok; MK, molecular weight marker; AUC, area under 859 
curve 860 
 861 
Figure 6 Vaccination with MAV preparations protects mice against S. pneumoniae 862 
challenge. A Lung and B blood CFU 24 hours after challenge by intranasal inoculation with 1 863 
x 107 CFU S. pneumoniae TIGR4 strain of mice vaccinated twice subcutaneously with 75 μg 864 
of MAV or a negative control buffer (n = 10 per group). C Nasal wash two weeks after 865 
nasopharyngeal colonisation with 5 x 106 CFU S. pneumoniae TIGR4 of mice vaccinated 866 
twice subcutaneously with 75 μg of MAV or a negative control buffer (n = 8 per group).  D 867 
Blood CFU 6 hours after challenge by intraperitoneal inoculation with 1 x 104 CFU S. 868 
pneumoniae TIGR4 strain of mice passively vaccinated with 200 μl of sera from rabbits 869 
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obtained from animals vaccinated three times with 375 µg of MAVIPS004, twice with 0.2 mL of 870 
Prevenar, or a negative control buffer (n = 12 per group). E and F  Blood CFU 4 hours in 871 
mice after challenge by intravenous inoculation with 5 x 105 CFU of the S. pneumoniae E 872 
TIGR4 or  F ATCC® BAA-1662 (18C) strains that have been incubated pre-inoculation in 873 
sera obtained from rabbits vaccinated with MAVIPS014, Prevenar, or a negative control buffer 874 
(n = 5 to 10). For all panels each symbol represents data from a single mouse, and 875 
horizontal bars represent median values. Statistical significances were calculated using a 876 
Mann Whitney t test (panels A to D) or Dunnett’s multiple comparisons test (panels E and F). 877 
Significance abbreviations: * = p < 0.05; ** = p < 0.01; *** = p < 0.001. 878 
 879 
Figure 7 Vaccination with MAV preparations increase survival of mice and alters the 880 
inflammatory response after TIGR4 S. pneumoniae pneumonia challenge. A Percentage 881 
survival of mice over 6 days after challenge by intranasal inoculation with 1 x 107 CFU S. 882 
pneumoniae TIGR4 strain of mice vaccinated three times (day 1, 10, 22) intraperitoneally 883 
with 75 μg of MAVIPS014 or a negative control buffer (n = 15 per group). Significance has 884 
been calculated using the log-rank (Mantel-Cox) test. B to D Target organ CFU (B), 885 
inflammatory cell populations in BALF (C) and lung (D) 24 h after challenge with 1 x 107 CFU 886 
S. pneumoniae TIGR4 strain in MAV IPS014 vaccinated and control mice.  Inflammatory cell 887 
data are shown as a percentage of total cells recovered from lungs of MAV- and buffer-888 
vaccinated mice; CFU data show lung, blood or BALF CFU recovered 24 h after challenge 889 
with each symbol representing data from a single mouse and horizontal bars represent 890 
median values.  E to H Lung homogenate cytokine levels (pg / ml) 24 h after challenge with 891 
1 x 107 CFU S. pneumoniae TIGR4 strain in MAVIPS014 vaccinated and control mice.  For 892 
panels (B) to (H) statistical significances were calculated using a Mann Whitney t test. 893 
Significance abbreviations: * = p < 0.05; ** = p < 0.01. 894 
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Table 1 Selected proteins that TMT-MS/MS analysis show have increased 1 
expression in the MAV TIGR4.1 compared to the TIGR4 HKL preparation.  2 
SP # Protein 
Fold 
change 
References 
Heat shock proteins 
SP_0338 Putative ATP-dependent Clp protease, ATP-binding  2.67 (60) 
SP_0517 Chaperone protein (DnaK) 4.33 (61, 62) 
SP_0516 Protein GrpE (GrpE) 3.03 (63, 64) 
SP_0519 Chaperone protein (DnaJ) 2.37 (65, 66) 
SP_1906 60 kDa chaperonin (GroL) 2.95 (67) 
SP_1907 10 kDa chaperonin (GroS) 3.56 (68) 
Known immunogens 
SP_0082 Cell wall surface anchor family protein (PavB) 5.33 (69) 
SP_0148 ABC transporter, substrate-binding protein  3.10 (70, 71) 
SP_0149 ABC transporter substrate binding protein (MetQ) 2.52 (70, 72) 
SP_0629 L,D-carboxypeptidase (DacB) 3.94 (73) 
SP_0845 Nucleoside ABC transporter protein 2.37 (74) 
SP_1032 Iron-compound ABC transporter (PiaA) 2.22 (47, 75) 
SP_1650 Manganese ABC transporter lipoprotein (PsaA) 4.03 (76, 77) 
SP_2093 Putative uncharacterized membrane protein 2.78 (78) 
SP_2108 Maltose/maltodextrin-binding protein (MalX) 3.19 (71) 
 3 
Only proteins with an increased fold change of 2 and above are shown 4 
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